ELI LILLY AND COMPANY Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component
ELI LILLY AND COMPANY (LLY) reported Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component of -$114.00 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent · last filed 2025-10-30
- ELI LILLY AND COMPANY net periodic defined benefits expense (reversal of expense), excluding service cost component for the quarter ending 2025-09-30 was -$114.00M.
- ELI LILLY AND COMPANY net periodic defined benefits expense (reversal of expense), excluding service cost component for the quarter ending 2025-06-30 was -$105.40M.
- ELI LILLY AND COMPANY net periodic defined benefits expense (reversal of expense), excluding service cost component for the quarter ending 2025-03-31 was -$106.60M.
- ELI LILLY AND COMPANY net periodic defined benefits expense (reversal of expense), excluding service cost component for the quarter ending 2024-12-31 was -$115.80M.
- ELI LILLY AND COMPANY net periodic defined benefits expense (reversal of expense), excluding service cost component for fiscal 2024 was -$461.70M.
- ELI LILLY AND COMPANY net periodic defined benefits expense (reversal of expense), excluding service cost component for fiscal 2023 was -$461.90M.
- ELI LILLY AND COMPANY net periodic defined benefits expense (reversal of expense), excluding service cost component for fiscal 2022 was -$372.90M.
- ELI LILLY AND COMPANY net periodic defined benefits expense (reversal of expense), excluding service cost component for fiscal 2021 was -$289.70M.
| Period end | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 3 month | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 3 month as first filed | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 6 month | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 6 month as first filed | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 9 month | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 9 month as first filed | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | -$114.00M 10-Q · filed 2025-10-30 | -$219.40M derived: sum of 2 quarters · filed 2025-10-30 | -$326.10M 10-Q · filed 2025-10-30 | -$441.80M derived: sum of 4 quarters · filed 2025-10-30 | |||
| 2025-06-30 | -$105.40M 10-Q · filed 2025-08-07 | -$212.00M 10-Q · filed 2025-08-07 | -$327.80M derived: sum of 3 quarters · filed 2025-08-07 | -$443.20M derived: sum of 4 quarters · filed 2025-10-30 | |||
| 2025-03-31 | -$106.60M 10-Q · filed 2025-05-01 | -$222.40M derived: sum of 2 quarters · filed 2025-05-01 | -$337.80M derived: sum of 3 quarters · filed 2025-10-30 | -$452.20M derived: sum of 4 quarters · filed 2025-10-30 | |||
| 2024-12-31 | -$115.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$231.20M derived: sum of 2 quarters · filed 2025-10-30 | -$345.60M derived: sum of 3 quarters · filed 2025-10-30 | -$461.70M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | -$115.40M 10-Q · filed 2025-10-30 | -$229.80M derived: sum of 2 quarters · filed 2025-10-30 | -$345.90M 10-Q · filed 2025-10-30 | -$460.90M derived: sum of 4 quarters · filed 2025-10-30 | |||
| 2024-06-30 | -$114.40M 10-Q · filed 2025-08-07 | -$230.50M 10-Q · filed 2025-08-07 | -$345.50M derived: sum of 3 quarters · filed 2025-08-07 | -$461.00M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$116.10M 10-Q · filed 2025-05-01 | -$231.10M derived: sum of 2 quarters · filed 2025-05-01 | -$346.60M derived: sum of 3 quarters · filed 2025-05-01 | -$462.20M derived: sum of 4 quarters · filed 2025-05-01 | |||
| 2023-12-31 | -$115.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$230.50M derived: sum of 2 quarters · filed 2025-02-19 | -$346.10M derived: sum of 3 quarters · filed 2025-02-19 | -$461.90M 10-K · filed 2025-02-19 | |||
| 2023-09-30 | -$115.50M 10-Q · filed 2024-10-30 | -$231.10M derived: sum of 2 quarters · filed 2024-10-30 | -$346.90M 10-Q · filed 2024-10-30 | -$439.80M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | -$115.60M 10-Q · filed 2024-08-08 | -$231.40M 10-Q · filed 2024-08-08 | -$324.30M derived: sum of 3 quarters · filed 2025-02-19 | -$416.70M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | -$115.80M 10-Q · filed 2024-04-30 | -$208.70M derived: sum of 2 quarters · filed 2025-02-19 | -$301.10M derived: sum of 3 quarters · filed 2025-02-19 | -$395.40M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | -$92.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$185.30M derived: sum of 2 quarters · filed 2025-02-19 | -$279.60M derived: sum of 3 quarters · filed 2025-02-19 | -$372.90M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | -$92.40M 10-Q · filed 2023-11-02 | -$186.70M derived: sum of 2 quarters · filed 2023-11-02 | -$280.00M 10-Q · filed 2023-11-02 | -$352.60M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | -$94.30M 10-Q · filed 2023-08-08 | -$187.60M 10-Q · filed 2023-08-08 | -$260.20M derived: sum of 3 quarters · filed 2024-02-21 | -$332.80M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | -$93.30M 10-Q · filed 2023-04-27 | -$165.90M derived: sum of 2 quarters · filed 2024-02-21 | -$238.50M derived: sum of 3 quarters · filed 2024-02-21 | -$309.60M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | -$72.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$145.20M derived: sum of 2 quarters · filed 2024-02-21 | -$216.30M derived: sum of 3 quarters · filed 2024-02-21 | -$289.70M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | -$72.60M 10-Q · filed 2022-11-01 | -$143.70M derived: sum of 2 quarters · filed 2022-11-01 | -$217.10M 10-Q · filed 2022-11-01 | -$274.40M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-06-30 | -$71.10M 10-Q · filed 2022-08-04 | -$144.50M 10-Q · filed 2022-08-04 | -$201.80M derived: sum of 3 quarters · filed 2023-02-22 | -$315.80M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-03-31 | -$73.40M 10-Q · filed 2022-04-29 | -$130.70M derived: sum of 2 quarters · filed 2023-02-22 | -$244.70M derived: sum of 3 quarters · filed 2023-02-22 | -$280.60M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2020-12-31 | -$57.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$171.30M derived: sum of 2 quarters · filed 2023-02-22 | -$207.20M derived: sum of 3 quarters · filed 2023-02-22 | -$251.80M 10-K · filed 2023-02-22 | |||
| 2020-09-30 | -$114.00M 10-Q · filed 2021-10-27 | -$149.90M derived: sum of 2 quarters · filed 2021-10-27 | -$194.50M 10-Q · filed 2021-10-27 | -$246.50M derived: sum of 4 quarters · filed 2022-02-23 | |||
| 2020-06-30 | -$35.90M 10-Q · filed 2021-08-03 | -$80.50M 10-Q · filed 2021-08-03 | -$132.50M derived: sum of 3 quarters · filed 2022-02-23 | -$184.70M derived: sum of 4 quarters · filed 2022-02-23 | |||
| 2020-03-31 | -$44.60M 10-Q · filed 2021-04-30 | -$96.60M derived: sum of 2 quarters · filed 2022-02-23 | -$148.80M derived: sum of 3 quarters · filed 2022-02-23 | -$198.60M derived: sum of 4 quarters · filed 2022-02-23 | |||
| 2019-12-31 | -$52.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$104.20M derived: sum of 2 quarters · filed 2022-02-23 | -$154.00M derived: sum of 3 quarters · filed 2022-02-23 | -$209.90M 10-K · filed 2022-02-23 | |||
| 2019-09-30 | -$52.20M 10-Q · filed 2020-10-28 | -$102.00M derived: sum of 2 quarters · filed 2020-10-28 | -$157.90M 10-Q · filed 2020-10-28 | -$225.10M derived: sum of 4 quarters · filed 2021-02-17 | |||
| 2019-06-30 | -$49.80M 10-Q · filed 2020-07-31 | -$105.70M 10-Q · filed 2020-07-31 | -$172.90M derived: sum of 3 quarters · filed 2021-02-17 | -$235.40M derived: sum of 4 quarters · filed 2021-02-17 | |||
| 2019-03-31 | -$55.90M 10-Q · filed 2020-05-01 | -$123.10M derived: sum of 2 quarters · filed 2021-02-17 | -$185.60M derived: sum of 3 quarters · filed 2021-02-17 | -$240.40M derived: sum of 4 quarters · filed 2021-02-17 | |||
| 2018-12-31 | -$67.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$129.70M derived: sum of 2 quarters · filed 2021-02-17 | -$184.50M derived: sum of 3 quarters · filed 2021-02-17 | -$240.50M 10-K · filed 2021-02-17 | |||
| 2018-09-30 | -$62.50M 10-Q · filed 2019-10-25 | -$62.90M 10-Q · filed 2018-11-06 | -$117.30M derived: sum of 2 quarters · filed 2019-10-25 | -$173.30M 10-Q · filed 2019-10-25 | -$174.20M 10-Q · filed 2018-11-06 | -$231.00M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-06-30 | -$54.80M 10-Q · filed 2019-08-02 | -$54.90M 10-Q · filed 2018-07-25 | -$110.80M 10-Q · filed 2019-08-02 | -$111.30M 10-Q · filed 2018-07-25 | -$168.50M derived: sum of 3 quarters · filed 2020-02-19 | -$232.30M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-03-31 | -$56.00M 10-Q · filed 2019-05-02 | -$113.70M derived: sum of 2 quarters · filed 2020-02-19 | -$177.50M derived: sum of 3 quarters · filed 2020-02-19 | -$241.80M derived: sum of 4 quarters · filed 2020-02-19 | |||
| 2017-12-31 | -$57.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | -$121.50M derived: sum of 2 quarters · filed 2020-02-19 | -$185.80M derived: sum of 3 quarters · filed 2020-02-19 | -$249.00M 10-K · filed 2020-02-19 | |||
| 2017-09-30 | -$63.80M 10-Q · filed 2018-11-06 | -$128.10M derived: sum of 2 quarters · filed 2018-11-06 | -$191.30M 10-Q · filed 2018-11-06 | ||||
| 2017-06-30 | -$64.30M 10-Q · filed 2018-07-25 | -$127.50M 10-Q · filed 2018-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |